Delaware federal judge reverses jury verdict in CareDx’s favour | Natera’s patents covering organ transplant testing ...

The test has met coverage requirements for use with patients with non-small cell lung cancer with resectable or unresectable disease in the surveillance setting.

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Guardant Health (GH) one of those stocks right now? By taking ...

In addition to the coverage in NSCLC, Signatera is also covered by Medicare for adjuvant and recurrence monitoring in colorectal cancer, muscle-invasive bladder cancer, breast cancer, and ovarian ...

Guggenheim restated their buy rating on shares of Guardant Health (NASDAQ:GH – Free Report) in a report released on Monday ...

A federal judge on Monday threw out a $96 million jury verdict against genetic testing company CareDX that rival Natera had ...

The lawsuit claims Natera aggressively recruited bioinformatics scientists from Guardant to “jumpstart its lagging position ...

Guardant Health (NASDAQ:GH – Get Free Report) had its target price boosted by research analysts at The Goldman Sachs Group ...

Medical diagnostics company Guardant Health has sued rival Natera in California federal court for allegedly stealing trade ...

As of December 2024, Guardant held $840 million of cash and marketable securities. However, it burned through approximately $390 million in 2022, $345 million in 2023, and $275 million in 2024.

BTIG raised the firm’s price target on Guardant Health (GH) to $60 from $55 and keeps a Buy rating on the shares after its Q4 earnings beat and ...

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based ...